scholarly journals Smoking increases oral mucosa susceptibility to Candida albicans infection via the Nrf2 pathway: In vitro and animal studies

2021 ◽  
Author(s):  
Pei Ye ◽  
Wei Chen ◽  
Fan Huang ◽  
Qin Liu ◽  
Ya‐Nan Zhu ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Oral Mucosa ◽  
Animal Studies ◽  
Nrf2 Pathway ◽  
Candida Albicans Infection

scholarly journals Antifungal susceptibility of Candida albicans isolated from oral mucosa of patients with cancer

1999 ◽  
Vol 13 (3) ◽  
pp. 219-223 ◽  
Author(s):  
Lino João da COSTA ◽  
Esther Goldenberg BIRMAN ◽  
Sidney Hartz ALVES ◽  
Arlete Emily CURY
Keyword(s):  
Candida Albicans ◽  
Cancer Patients ◽  
Amphotericin B ◽  
Oral Mucosa ◽  
Antifungal Susceptibility ◽  
New Drugs ◽  
Local Conditions ◽  
Opportunistic Fungi ◽  
Sabouraud Agar

The increasing number of oral infections due to opportunistic fungi in immunocompromised patients, needs a new evaluation of the drugs in use. The susceptibility in vitro of Candida albicans strains from the oral mucosa of cancer patients to amphotericin B, ketoconazole, miconazole, fluconazole and itraconazole were evaluated. A dilution technique in YNB agar or subculture on Sabouraud agar was utilised for MIC or MFC determinations. With this methodology, the best fungicidal drug for C.albicans collected from the oral mucosa of 40 cancer patients, divided in two groups: one treated by radiotherapy and the other not, the best results were obtained with amphotericin B, presenting low values of MIC compared to azoles and MFC values. However it is important to take into consideration the utilisation in vivo of this polyenic antibiotic and the possible toxic levels necessary to achieve good results. The coexistence of other fungi and the local conditions must also be pondered with these patients, who are mostly undergoing radiotherapy. In order to achieve better results without undesirable consequences, higher levels of MIC are expected with the daily clinical use of new drugs.

scholarly journals Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?

1995 ◽  
Vol 39 (10) ◽  
pp. 2197-2200 ◽  
Author(s):  
J. R. Graybill ◽  
L. K. Najvar ◽  
J. D. Holmberg ◽  
A. Correa ◽  
M. F. Luther
Keyword(s):  
Candida Albicans ◽  
In Vitro Susceptibility ◽  
Candida Albicans Infection

scholarly journals Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model

2000 ◽  
Vol 44 (6) ◽  
pp. 1463-1469 ◽  
Author(s):  
Leila Zarif ◽  
John R. Graybill ◽  
David Perlin ◽  
Laura Najvar ◽  
Rosie Bocanegra ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antifungal Activity ◽  
Amphotericin B ◽  
Blood Cells ◽  
Inhibitory Concentration ◽  
Human Red Blood Cells ◽  
Unique Shape ◽  
Tissue Burden ◽  
Candida Albicans Infection

ABSTRACT Cochleates are lipid-based supramolecular assemblies composed of natural products, negatively charged phospholipid, and a divalent cation. Cochleates can encapsulate amphotericin B (AmB), an important antifungal drug. AmB cochleates (CAMB) have a unique shape and the ability to target AmB to fungi. The minimal inhibitory concentration and the minimum lethal concentration against Candida albicans are similar to that for desoxycholate AmB (DAMB; Fungizone). In vitro, CAMB induced no hemolysis of human red blood cells at concentrations of as high as 500 μg of AmB/ml, and DAMB was highly hemolytic at 10 μg of AmB/ml. CAMB protect ICR mice infected with C. albicans when the agent is administered intraperitoneally at doses of as low as 0.1 mg/kg/day. In a tissue burden study, CAMB, DAMB, and AmBisome (liposomal AmB; LAMB) were effective in the kidneys, but in the spleen CAMB was more potent than DAMB at 1 mg/kg/day and was equivalent to LAMB at 10 mg/kg/day. In summary, CAMB are highly effective in treating murine candidiasis and compare well with AmBisome and AmB.

scholarly journals N-acetyl cysteine prevents pain and hypersensitivity of bleaching agents without affecting their aesthetic appeal; evidence from in vitro to animal studies and to human clinical trials

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Diana Wang ◽  
Kawaljit Kaur ◽  
Avina Paranjpe ◽  
Eric Lee ◽  
Matthew Wasilewski ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Side Effects ◽  
Oral Mucosa ◽  
Animal Studies ◽  
In Vitro Assays ◽  
Electron Microscopic ◽  
Adverse Side Effects ◽  
Acetyl Cysteine

Abstract Background Tooth hypersensitivity and pain are undesirable side effects of bleaching agents in humans. The aim of this study is to implement strategies to counter such side effects, and to demonstrate the efficacy and mechanisms of action of N-acetyl cysteine (NAC) in countering the side effects of clinically used bleaching agents. Methods In a series of in vitro experiments, animal model studies, and human clinical trials, we demonstrate that NAC protects oral mucosa and teeth from damage induced by bleaching agents. Results The addition of NAC along with clinically used bleaching agents to dental pulp stromal/stem cells (DPSCs), stem-cells of apical papillae (SCAP) and oral epithelial cells, inhibited cell death mediated by bleaching agents in several in vitro assays. In addition, rat teeth, when treated with chair-side or over-the-counter bleaching agents, exerted adverse side effects to pulpal and gingival tissues as evidenced by the white lesions of gingivae as well as decreased survival and function of DPSCs. These side effects of bleaching agents were greatly mitigated by the application of NAC to the surfaces of the teeth and to the oral mucosa. NAC protected the surface topography and the appearance of the tissues after bleaching using scanning electron microscopic (SEM) analysis. Finally, application of NAC prior to the bleaching demonstrated significant translational benefit for the patients since it ameliorated pain and hypersensitivity and protected gingivae from bleaching induced white lesions and improved inflammatory index in the oral mucosa in human clinical trials. Conclusions Therefore, application of NAC to the surfaces of the teeth and oral mucosa prior to the use of bleaching materials is beneficial for countering adverse side effects of bleaching in patients and decreases pain, sensitivity, and potential damage to the dentition and oral mucosa associated with bleaching. Trial registration NCT03534115 (NAC Prevents Side-Effects of Teeth Bleaching). Registration 4 December 2014.

Sign in / Sign up

Export Citation Format

Share Document